A multi-site clinical trial is currently underway in the U.S. and in Israel. Information on the neuroAD study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01825330?term=NCT+01825330&rank=1
To learn more about additional sites in other locations throughout the world, or for more information about participating in a clinical trial, please contact Neuronix at firstname.lastname@example.org
Currently these centers are participating in the study:
Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, Nevada, U.S.
Contact person: Yolande Mucharbach
Palm Beach Neurology and Premiere Research Institute, West Palm Beach, Florida, U.S.
Contact person: Dr. Teresa Villena
Beth Israel Deaconess Medical Center, Boston, Massachusetts, U.S.
Contact person: Avi Fuld
Banner Sun Health Research Institute, Sun City, Arizona, U.S.
Contact person: Carolyn Liebsack
NYU Langone Medical Center, New York, New York, U.S.
Contact person: Christina Michel
Cleveland Clinic, Cleveland, Ohio, US
Contact person: Christine Whitman
Miami Jewish Health Systems, Miami, FL, U.S.
Contact person: Jose G. Macias
Asaf Harofe Hospital, Beer Yakov, Zrifin, Israel
Contact person: Liat Yahimovitch
ATP Clinical Research, Costa Mesa, California, U.S.
Contact person: Bobby Shih
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.